Werewolf Therapeutics Inc’s filing revealed that its Director EVNIN LUKE unloaded Company’s shares for reported $38198.0 on Nov 26 ’25. In the deal valued at $0.98 per share,38,978 shares were sold. As a result of this transaction, EVNIN LUKE now holds 3,248,573 shares worth roughly $2.99 million.
Then, EVNIN LUKE sold 39,096 shares, generating $36,750 in total proceeds. Upon selling the shares at $0.94, the Director now owns 3,196,463 shares.
Before that, EVNIN LUKE sold 13,014 shares. Werewolf Therapeutics Inc shares valued at $12,884 were divested by the Director at a price of $0.99 per share. As a result of the transaction, EVNIN LUKE now holds 3,235,559 shares, worth roughly $2.98 million.
JMP Securities initiated its Werewolf Therapeutics Inc [HOWL] rating to a Mkt outperform in a research note published on April 03, 2024; the price target was $12. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in late August with a ‘”an Outperform”‘ rating. BofA Securities started covering the stock on September 10, 2021. It rated HOWL as “a Buy”.
Price Performance Review of HOWL
On Monday, Werewolf Therapeutics Inc [NASDAQ:HOWL] saw its stock fall -8.32% to $0.92. Over the last five days, the stock has gained 4.99%. Werewolf Therapeutics Inc shares have fallen nearly -53.22% since the year began. Nevertheless, the stocks have fallen -38.05% over the past one year. While a 52-week high of $2.38 was reached on 09/29/25, a 52-week low of $0.60 was recorded on 04/07/25.
Levels Of Support And Resistance For HOWL Stock
The 24-hour chart illustrates a support level at 0.8812, which if violated will result in even more drops to 0.8456. On the upside, there is a resistance level at 0.9762. A further resistance level may holdings at 1.0356.
How much short interest is there in Werewolf Therapeutics Inc?
A steep rise in short interest was recorded in Werewolf Therapeutics Inc stocks on 2025-11-14, dropping by 50079.0 shares to a total of 0.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 0.82 million shares. There was a decline of -6.47%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 25, 2021 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $29 price target.
